Theriva Biologics Inc
TOVX
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.36M
Close$
$0.86
246.8% upside
Current Fair Value
246.8% upsideUndervalued by 246.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.36 Million |
|---|---|
| Enterprise Value | $3.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.08 |
| Beta | 1.15 |
| Outstanding Shares | 45,892,668 |
Return
| Return on Equity | -107.72% |
|---|---|
| Return on Assets | -37.66% |
| Return on Invested Capital | -52.18% |
Valuation & Multiples
| P/E Ratio | -0.37 |
|---|---|
| PEG | 0.49 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 11.93 |
| Enterprise Value to EBIT | -0.3 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$300,000
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.32%▼ 0.47% |
|---|---|
| Total Invested | $495,531▲ 28.59% |
| Investors Holding | 24▲ 4.00% |
ESG Score
No data
About Theriva Biologics Inc
10 employees
CEO: Steven Shallcross Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates ...